Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
ConclusionsThis case and the review of current data confirm the benefit of BRAF inhibition in BRAF-mutated ATC, limited by acquired resistance to targeted therapy.
Source: Thyroid Research - Category: Endocrinology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Endocrinology | Genetics | Hairy Cell Leukemia | Leukemia | Melanoma | PET Scan | Radioiodine Therapy | Skin Cancer | Thyroid | Thyroid Cancer